BR112018008068A2 - moléculas de ligação que inibem o crescimento do câncer - Google Patents

moléculas de ligação que inibem o crescimento do câncer

Info

Publication number
BR112018008068A2
BR112018008068A2 BR112018008068A BR112018008068A BR112018008068A2 BR 112018008068 A2 BR112018008068 A2 BR 112018008068A2 BR 112018008068 A BR112018008068 A BR 112018008068A BR 112018008068 A BR112018008068 A BR 112018008068A BR 112018008068 A2 BR112018008068 A2 BR 112018008068A2
Authority
BR
Brazil
Prior art keywords
binding molecules
cancer growth
inhibit cancer
antibodies
membrane associated
Prior art date
Application number
BR112018008068A
Other languages
English (en)
Inventor
Throsby Mark
Logtenberg Ton
Carolus Clevers Johannes
Gerhardus Jacob Vries Robert
Batlle Eduard
Herpers Bram
Original Assignee
Merus N.V.
Koninklijke Nederlandse Akademie Van Wetenschappen
Ocello B.V.
Institute For Research In Biomedicine (Irb Barcelona)
Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus N.V., Koninklijke Nederlandse Akademie Van Wetenschappen, Ocello B.V., Institute For Research In Biomedicine (Irb Barcelona), Institució Catalana De Recerca I Estudis Avançats filed Critical Merus N.V.
Publication of BR112018008068A2 publication Critical patent/BR112018008068A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção fornece meios e métodos para inibir o crescimento de um câncer. os meios, em algumas modalidades, compreendem proteínas e anticorpos que se ligam a uma parte extracelular de um membro associado à membrana da família de receptores do fator de crescimento epidérmico (egf) e uma parte extracelular de um membro associado à membrana de uma via de sinalização de wnt. são adicionalmente fornecidas várias células e ensaios que são úteis na produção das proteínas, anticorpos e células.
BR112018008068A 2015-10-23 2016-10-21 moléculas de ligação que inibem o crescimento do câncer BR112018008068A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06
PCT/NL2016/050726 WO2017069628A2 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth

Publications (1)

Publication Number Publication Date
BR112018008068A2 true BR112018008068A2 (pt) 2018-11-13

Family

ID=57190021

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008068A BR112018008068A2 (pt) 2015-10-23 2016-10-21 moléculas de ligação que inibem o crescimento do câncer

Country Status (26)

Country Link
US (1) US11939394B2 (pt)
EP (2) EP3365373B1 (pt)
JP (3) JP7296728B2 (pt)
KR (1) KR20180100305A (pt)
CN (2) CN108602888B (pt)
AU (2) AU2016340764B2 (pt)
BR (1) BR112018008068A2 (pt)
CA (1) CA3002957A1 (pt)
CY (1) CY1124108T1 (pt)
DK (1) DK3365373T3 (pt)
EA (1) EA201890866A1 (pt)
ES (1) ES2865482T3 (pt)
HK (1) HK1253914A1 (pt)
HR (1) HRP20210483T1 (pt)
HU (1) HUE055222T2 (pt)
LT (1) LT3365373T (pt)
MA (2) MA45517B1 (pt)
MD (1) MD3365373T2 (pt)
MX (2) MX2018004988A (pt)
NZ (1) NZ742290A (pt)
PL (1) PL3365373T3 (pt)
RS (1) RS61800B1 (pt)
SG (1) SG11201803359VA (pt)
SI (1) SI3365373T1 (pt)
WO (1) WO2017069628A2 (pt)
ZA (1) ZA201802758B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
KR102352573B1 (ko) * 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
AU2018207440B2 (en) * 2017-01-11 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (RSPO) surrogate molecules
CA3050133A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
US11732043B2 (en) * 2017-07-06 2023-08-22 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
KR20200042467A (ko) * 2017-07-06 2020-04-23 메뤼스 엔.페. 이중특이적 항pd-1 tim3 항체
TW201910354A (zh) 2017-08-09 2019-03-16 荷蘭商美勒斯公司 結合表皮生長因子受體(EGFR)及cMET的抗體
AU2019243665B2 (en) * 2018-03-30 2023-06-01 Merus N.V. Multivalent antibody
EP3820499A4 (en) * 2018-07-09 2022-07-13 Surrozen Operating, Inc. TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND THEIR USES
EP3886905A4 (en) * 2018-12-27 2022-08-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. BISPECIFIC ANTIBODY FOR MEMBRANE REMOVAL OF TARGET RECEPTORS
JP7440516B2 (ja) 2018-12-31 2024-02-28 メルス ナムローゼ フェンノートシャップ 切断多価多量体
AU2019418280B2 (en) 2018-12-31 2023-01-05 Merus N.V. Mixed binding domains
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
AU2020331879A1 (en) * 2019-08-19 2022-02-24 Merus N.V. Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor.
BR112022008201A2 (pt) * 2019-11-01 2022-07-12 Univ California Degradação de proteínas de superfície usando agente de ligação biespecífico
EP4114854A1 (en) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
KR20230005281A (ko) 2020-04-24 2023-01-09 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
CA3178265A1 (en) * 2020-06-18 2021-12-23 Umc Utrecht Holding B.V. Screening method for effective target - e3 ligase combinations
CN113862326A (zh) * 2020-09-08 2021-12-31 复旦大学 KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
IL303633A (en) 2020-12-15 2023-08-01 Merus Nv Cancer treatment with an antibody that binds LGR5 and EGFR
WO2022131918A1 (en) * 2020-12-18 2022-06-23 Merus N.V. Antibody composition
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
TW202321309A (zh) 2021-10-06 2023-06-01 荷蘭商美勒斯公司 使用至少結合ｅｇｆｒ之抗體治療免疫檢查點抑制劑治療之具高ｅｇｆｒ表現的癌症
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
IE922287A1 (en) 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 Missel Gmbh & Co E Trägersystem für Bade-, Dusch- oder Whirlwannen
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1533380T3 (da) 1999-04-15 2010-02-01 Crucell Holland Bv Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
DE29915950U1 (de) 1999-09-10 1999-12-30 Cmw Automation Gmbh Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ATE466943T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
EP1762617A1 (en) 2003-01-07 2007-03-14 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
US9212230B2 (en) 2007-03-29 2015-12-15 Genmab A/S Bispecific antibodies and methods for production thereof
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US9404928B2 (en) 2008-02-05 2016-08-02 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
CN102365296A (zh) 2009-01-26 2012-02-29 根马布股份公司 用于生成抗体混合物的方法
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
CN103080134B (zh) 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
CA2828099A1 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR20140023921A (ko) 2011-03-15 2014-02-27 메리맥 파마슈티컬즈, 인크. ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법
EP2688909A2 (en) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
PL2707391T3 (pl) 2011-05-13 2018-04-30 Gamamabs Pharma Przeciwciała przeciwko her3
EP2722343A4 (en) 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-ERBB3 ANTIBODIES
AU2012284254B2 (en) * 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US8791244B2 (en) 2011-09-30 2014-07-29 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
EP2797957B1 (en) 2011-11-23 2019-06-19 MedImmune, LLC Binding molecules specific for her3 and uses thereof
EP2788381A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
WO2013134686A1 (en) 2012-03-09 2013-09-12 Promega Corporation pH SENSORS
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
SI2922872T1 (sl) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
WO2014159580A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
KR102352573B1 (ko) 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
EP3115376B1 (en) 2015-07-10 2018-09-05 Merus N.V. Human cd3 binding antibody
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
EP3600411A1 (en) 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
US20210054096A1 (en) 2017-05-17 2021-02-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
TW201910354A (zh) 2017-08-09 2019-03-16 荷蘭商美勒斯公司 結合表皮生長因子受體(EGFR)及cMET的抗體
JP2022516071A (ja) * 2018-12-27 2022-02-24 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Also Published As

Publication number Publication date
EP3912998A2 (en) 2021-11-24
HK1253914A1 (zh) 2019-07-05
JP7296728B2 (ja) 2023-06-23
RS61800B1 (sr) 2021-06-30
KR20180100305A (ko) 2018-09-10
MD3365373T2 (ro) 2021-08-31
DK3365373T3 (da) 2021-04-06
HRP20210483T1 (hr) 2021-07-09
SG11201803359VA (en) 2018-05-30
ES2865482T3 (es) 2021-10-15
MX2018004988A (es) 2018-11-09
EP3365373B1 (en) 2021-03-10
JP2019500405A (ja) 2019-01-10
US11939394B2 (en) 2024-03-26
NZ742290A (en) 2019-11-29
HUE055222T2 (hu) 2021-11-29
AU2016340764B2 (en) 2023-06-01
CN115925944A (zh) 2023-04-07
PL3365373T3 (pl) 2021-08-23
WO2017069628A9 (en) 2017-10-26
CA3002957A1 (en) 2017-04-27
US20180312604A1 (en) 2018-11-01
ZA201802758B (en) 2020-08-26
EP3365373A2 (en) 2018-08-29
MA45517A (fr) 2018-08-29
WO2017069628A3 (en) 2017-09-08
MA45517B1 (fr) 2021-04-30
SI3365373T1 (sl) 2021-08-31
MX2022000302A (es) 2022-02-03
LT3365373T (lt) 2021-05-25
AU2016340764A1 (en) 2018-05-17
WO2017069628A2 (en) 2017-04-27
CY1124108T1 (el) 2022-05-27
JP2023008754A (ja) 2023-01-19
JP2024023445A (ja) 2024-02-21
AU2023222928A1 (en) 2023-09-21
EP3912998A3 (en) 2022-02-23
CN108602888A (zh) 2018-09-28
MA54760A (fr) 2022-04-13
EA201890866A1 (ru) 2018-09-28
CN108602888B (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
BR112018008068A2 (pt) moléculas de ligação que inibem o crescimento do câncer
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
CL2021001603A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
BR112017020054A2 (pt) anticorpos para icos
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
MX2018015704A (es) Control de fluidos.
BR112018001531A2 (pt) construtos de anticorpo para cd70 e cd3
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
AR105266A1 (es) Anticuerpos de unión a tau y sus fragmentos enlazantes
UY35456A (es) Moléculas de unión para bcma y cd3
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
BR112020000209A8 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
BR112018015965A2 (pt) método para determinação de helicobacter pylori
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
BR112017012515A2 (pt) membros vinculantes para c-maf humano
BR112016024462A2 (pt) ?métodos para a preparação de uma proteína, proteína heteromultimérica, composição e célula hospedeira?
BR112019003712A2 (pt) composições marcadoras, e métodos para produção e uso das mesmas
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERUS N.V. (NL) ; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) ; OCELLO B.V. (NL) ; INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) ; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)

B25A Requested transfer of rights approved

Owner name: MERUS N.V. (NL) ; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) ; INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) ; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) ; CROWN BIOSCIENCE NETHERLANDS B.V. (NL)

B25A Requested transfer of rights approved

Owner name: MERUS N.V. (NL) ; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) ; INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) ; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)

B25A Requested transfer of rights approved

Owner name: MERUS N.V. (NL) ; INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) ; FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)